PHARMACY

Winn-Dixie makes flu vaccinations available at its pharmacies

BY Michael Johnsen

JACKSONVILLE, Fla. Winn-Dixie Stores on Monday rolled out a month-long program offering customers flu and pneumonia vaccinations, and will extend discounts on those vaccinations to Winn-Dixie Customer Reward cardholders.

The grocer is also offering free cholesterol and diabetes screenings at its more than 400 in-store pharmacies.

“Winn-Dixie wants to make a healthy lifestyle an easy choice for our customers,” stated Michael LeBlanc, director of pharmacy. “Offering these vaccines and free health screenings is one more way we are getting better at being a good neighbor to the communities we serve.”

Members of Winn-Dixie’s frequent shopper will pay $28 for the flu vaccine ($30 for non-cardholders) and $38 for the pneumonia vaccine ($45 for non-cardholders).

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Shopko donates school supplies to Green Bay area elementary school

BY Alaric DeArment

GREEN BAY, Wis. An elementary school in Green Bay received a variety of school supplies from a locally headquartered retail chain.

Shopko announced Oct. 2 that it had donated the supplies to Sunrise River Elementary, which serves students in second through fifth grade. The supplies included basic items from the school’s required supply list.

Shopko operates stores throughout the Midwest and West.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ARCA Biopharma makes unprecedented payment to Aeolus following FDA approval of bucindolol

BY Alaric DeArment

NEW YORK Aeolus Pharmaceuticals announced Friday that it had received a $175,000 milestone payment from ARCA Biopharma following the Food and Drug Administration’s acceptance of an approval application for a cardiovascular drug.

Aeolus said the drug, bucindolol, could be the first genetically targeted cardiovascular therapy. CPEC, a company owned jointly by Aeolus and Indevus Pharmaceuticals, licensed all rights to bucindolol to ARCA.

“ARCA’s success in demonstrating the potential benefits of bucindolol in treating heart failure in patients is encouraging,” Aeolus president and chief executive officer John McManus said in a statement. “We look forward to an expeditious review and hope for a positive outcome.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?